Strattera vs Wellbutrin: Key Differences for ADHD and Depression

Strattera (atomoxetine) and Wellbutrin (bupropion) are both non-stimulant medications that affect norepinephrine, a brain chemical involved in attention, alertness, and mood. Strattera is FDA-approved to treat ADHD, while Wellbutrin is approved for depression and is sometimes prescribed off-label for ADHD. Understanding how they differ can help you have a more informed conversation with your prescriber about which option could fit your needs.

Key Takeaways

• Both take time to work: Unlike stimulants, Strattera may begin to help within one to two weeks, but it often needs four to eight weeks to reach its full effect. Wellbutrin may also take several weeks to affect ADHD symptoms, but the evidence for its use in ADHD is more limited.

• They're approved for different conditions: Strattera is FDA-approved for ADHD in adults and children 6 and older, while Wellbutrin is approved for depression and seasonal affective disorder and has more limited evidence for ADHD.

• Your full health picture matters: Tell your prescriber about seizures, eating disorders, heart or liver problems, other medications, and mood symptoms, since these can shape which medication is the safer choice.

What is the Difference Between Strattera and Wellbutrin?

Although both medications are non-stimulants that influence norepinephrine, they work in slightly different ways and were developed for different purposes. Here's a closer look at each one.

What is Strattera?

Strattera is the brand name for atomoxetine, a selective norepinephrine reuptake inhibitor. It blocks the reabsorption of norepinephrine, which helps keep more of it available in areas of the brain linked to attention and impulse control. Atomoxetine was the first non-stimulant medication approved by the FDA for ADHD, and it's approved for children 6 and older, teens, and adults.

Because Strattera isn't a controlled substance, it may appeal to people who want to avoid stimulants or have concerns about misuse. Clinical reviews have found little evidence of misuse or abuse potential. Strattera is one of several options in the broader category of non-stimulant ADHD medication.

What is Wellbutrin?

Wellbutrin is the brand name for bupropion, an antidepressant that affects both norepinephrine and dopamine. It is FDA-approved for major depressive disorder and seasonal affective disorder, and another bupropion product, named Zyban, is approved to help people quit smoking. Unlike some antidepressants, Wellbutrin isn't an SSRI, so it doesn't act mainly on serotonin.

Wellbutrin isn’t FDA-approved specifically for ADHD, but it is sometimes prescribed off-label for ADHD in adults. It may be considered when depression also needs treatment or when other ADHD medications are unsuitable, but evidence for its effectiveness in ADHD is more limited than the evidence supporting Strattera and stimulant medications.

Strattera vs Wellbutrin at a Glance

The table below summarizes some of the main differences between the two medications.

It is important to discuss any medication change with your provider rather than stopping or adjusting treatment on your own.

How Well Do Strattera and Wellbutrin Work for ADHD?

Both medications have shown benefits over placebo for adult ADHD, but the strength of the evidence differs. Researchers have compared them in large reviews that pool results from many clinical trials.

The Evidence for Strattera

A systematic review and meta-analysis from 2025 studied 113 trials and concluded that both atomoxetine and stimulants produced beneficial effects in reducing core ADHD symptoms compared to placebo. However, atomoxetine was less acceptable than placebo, which represents the proportion of patients who stopped treatment for any reason, including side effects. 

Because Strattera has been studied extensively and carries FDA approval for ADHD, it is one evidence-supported non-stimulant option when stimulants are unsuitable or not preferred. The order in which medications are considered depends on clinical history, local guidelines, and patient preferences.

The Evidence for Wellbutrin

Bupropion has shown potential benefits for ADHD symptoms in some adult clinical trials, but the evidence remains limited. A 2018 meta-analysis showed bupropion to be better than placebo, alongside stimulants and atomoxetine, although the 2025 follow-up study, mentioned earlier, did not include bupropion. 

At the same time, a 2017 Cochrane review concluded that the evidence for bupropion in adult ADHD is low quality but suggests a possible benefit, and that extended- or sustained-release bupropion may be an alternative to stimulants. 

Thus, bupropion may still be considered off-label for selected adults, but its effectiveness for ADHD is less firmly established.

How They Compare to Stimulants

On average, stimulant medications tend to reduce core ADHD symptoms more than non-stimulants, although not everyone benefits from or tolerates them. 

In the 2025 study, both stimulants, as a class, and atomoxetine demonstrated short-term benefits over placebo. The study also showed that atomoxetine was less-acceptable than placebo. Bupropion is sometimes used off-label when stimulants and other non-stimulants are not suitable or effective, though its evidence-base is more limited. 

Non-stimulants still play an important role for people who can't tolerate stimulants or have reasons to avoid them, and the trade-offs between stimulant vs. non-stimulant ADHD medications often guide that choice.

How Long Do Strattera and Wellbutrin Take to Work?

Neither medication works as quickly as a stimulant, which can take effect within an hour. Non-stimulant ADHD medications may start to help within one to two weeks, but it can take four to eight weeks to see their full effect.

Wellbutrin follows a similar gradual pattern. Some people notice more energy or better focus within the first couple of weeks, while improvements in mood and other ADHD symptoms may take longer. The exact timeline for Wellbutrin’s therapeutic responsevaries from person to person. As you wait for its effects to take hold, make sure to report persistent insomnia, agitation, or other troublesome changes to your prescriber. 

If you do not notice improvement after taking Wellbutrin or Strattera consistently for an adequate trial at a dose recommended by your provider, discuss this with your provider and do not abruptly discontinue. They may adjust the dose, put you on a different medication, or consider therapy for ADHD.

Strattera vs Wellbutrin Side Effects

Side effects differ between the two medications, and most are mild to moderate. Some side effects ease after the first few weeks as your body adjusts, while others may persist or require a change in dose or treatment.

Common Strattera Side Effects

Atomoxetine's most common side effects include:

• Nausea

• Dry mouth (adults)

• Decreased appetite and weight loss

• Dizziness

• Fatigue

• Insomnia (more in adults)

• Somnolence (more in children)

• Irritability

• Difficulty urinating (adults)

Strattera can also raise heart rate and blood pressure, so prescribers typically check cardiovascular health before treatment and assess heart rate and blood pressure after dose increases and periodically during treatment.

Common Wellbutrin Side Effects

Bupropion side effects often include:

• Dry mouth

• Insomnia

• Nausea

• Abdominal pain

• Constipation

• Agitation or anxiety

• Dizziness

• Tremors

• Racing heart (palpitations)

• Sweating

• Increased blood pressure

Wellbutrin is less likely than many antidepressants to cause weight gain or sexual side effects, which is one reason some people prefer it. It can increase blood pressure, so monitoring may be appropriate, particularly for people with hypertension or other cardiovascular risk factors. For people with anxiety, its activating effects can be a concern for some, though not all, and the research on whether Wellbutrin helps with anxiety is mixed.

Safety Warnings and Interactions

Both medications carry important safety information that your prescriber will review with you. Key points include:

• Suicidal thoughts in young people: Strattera has a boxed warning for increased suicidal thoughts in children and teens, and Wellbutrin carries the antidepressant boxed warning about an increased risk of suicidal thinking and behavior in children, adolescents, and young adults. Close monitoring is important when treatment begins and when doses change.

• Seizure risk with Wellbutrin: Wellbutrin lowers the seizure threshold in a dose-related manner. At doses up to 300 mg per day of the sustained-release form, the seizure rate is about 1 in 1,000 (0.1%), and the risk rises at higher doses. The incidence has not been formally evaluated in clinical trials of Wellbutrin XL, and individual risk depends on factors such as medical history, dose, and other medications.

• Conditions that may rule out Wellbutrin: It's contraindicated in people with a seizure disorder, a current or past diagnosis of anorexia nervosa or bulimia, and those abruptly stopping alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.

• Liver problems with Strattera: Rare cases of severe liver injury have been reported with Strattera. Contact a healthcare professional promptly if you develop yellowing of the skin or eyes, dark urine, unexplained flu-like symptoms, or abdominal pain that could indicate a liver problem..

• MAOI interactions: Both medications are contraindicated with monoamine oxidase inhibitors (MAOIs), an older type of antidepressant. They generally should not be taken until at least 14 days after stopping an MAOI. A prescriber should manage any switch between these medications.

• CYP2D6 interactions: Strattera is broken down mainly by the liver enzyme CYP2D6. People who process it slowly, either because they are poor CYP2D6 metabolizers or because they take medications that inhibit this enzyme, may have much higher blood levels and need dose adjustments. That is why it is important to tell your prescriber about all medications and supplements you take.

Which Might Be a Better Fit?

There's no single right answer, and your prescriber will weigh your symptoms, history, current medications, and goals before starting treatment. In general, each medication may be considered in different situations.

Strattera may be considered when:

• ADHD is the main concern and an FDA-approved non-stimulant is preferred

• Stimulants caused troublesome side effects or didn't work well enough

• Either the prescriber or patient want to avoid stimulant medication

• A prescriber is weighing options for ADHD with co-occurring anxiety

Wellbutrin may be considered when:

• Depression and ADHD symptoms occur together

• The person also wants help quitting smoking; a smoking-cessation formulation of bupropion may be an option when clinically appropriate

• Avoiding sexual side effects is a priority

• Other ADHD medications were tried and didn’t produce sufficient response

When to Seek Medical Attention

Some symptoms need prompt care while taking either medication. 

Contact your prescriber promptly if you notice:

• New or worsening thoughts of suicide or self-harm. Call or text 988 to reach the 988 Suicide & Crisis Lifeline. If you may act on thoughts of suicide or cannot keep yourself safe, seek immediate crisis support.

• Unusual changes in mood or behavior, such as agitation, aggression, or extreme restlessness

• Signs of possible liver injury, including yellowing of the skin or eyes, dark urine, or upper belly pain

Seek emergency care for:

• Seizures, fainting, or chest pain

• Signs of a serious allergic reaction, such as swelling of the face or throat or trouble breathing

How Blossom Health Can Help

Choosing between ADHD and depression medications can feel complicated, especially when symptoms overlap. Blossom Health connects you with board-certified psychiatric providers for virtual care, and every provider can evaluate your symptoms, discuss options like Strattera and Wellbutrin, and prescribe medication when appropriate.

Because neither Strattera nor Wellbutrin is a controlled substance, both can be prescribed through virtual visits when clinically appropriate. Blossom works with many insurance plans, so check your coverage and book a visit with a Blossom Health provider.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice. If you are in crisis or thinking about harming yourself, call or text 988 or call 911.

Sources

1. U.S. Food and Drug Administration. (2026). Strattera (atomoxetine) capsules prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf

2. U.S. Food and Drug Administration. (2025). Wellbutrin XL (bupropion hydrochloride extended-release tablets) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021515s049lbl.pdf

3. StatPearls. (March 27, 2023). Atomoxetine. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK493234/

4. StatPearls. (Accessed October 6, 2026). Bupropion. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK470212/

5. Medical Genetics Summaries. (Accessed October 6, 2026). Atomoxetine therapy and CYP2D6 genotype. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK315951/

6. Cortese S, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727-738. https://pmc.ncbi.nlm.nih.gov/articles/PMC6109107/

7. Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. (2017). Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, CD009504. https://pmc.ncbi.nlm.nih.gov/articles/PMC6485546/

8. Ostinelli, E. G., Schulze, M., Zangani, C., et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. The Lancet Psychiatry, 12(1), 32–43. https://doi.org/10.1016/S2215-0366(24)00360-2

9. Paediatric Drugs. (2003). Atomoxetine. Paediatric Drugs, 5(6), 407-415. https://pubmed.ncbi.nlm.nih.gov/12765489/

10. National Institute of Mental Health. (Accessed October 6, 2026). Mental health medications. https://www.nimh.nih.gov/health/topics/mental-health-medications